# Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2

> **NCT00544804** · PHASE1 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 41 (actual)

## Conditions studied

- Breast Cancer
- Metastatic Cancer

## Interventions

- **DRUG:** lapatinib ditosylate
- **GENETIC:** gene expression analysis
- **OTHER:** diagnostic laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00544804
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2013-06
- **Final completion:** 2013-12
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2014-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00544804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00544804, "Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00544804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*